Hemostatic Abnormalities and Relationships to Metabolic and Hormonal Status in Polycystic Ovarian Syndrome

Trends in Cardiovascular Medicine

Volumn 21, Issue 1, 2011, Pages 6-14

  Burchall, Genia ^a   Linden, Matthew D ^a   Teede, Helena ^b   Piva, Terrence J ^a  

^a RMIT UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 7; CLOMIFENE CITRATE; CYPROTERONE ACETATE; EFLORNITHINE; ESTROGEN; GONADOTROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; METFORMIN; PLASMINOGEN; PROTEIN C; PROTEIN S; SPIRONOLACTONE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; VON WILLEBRAND FACTOR;

AMENORRHEA AND OLIGOMENORRHEA; BODY MASS; CARDIOVASCULAR RISK; CELL FUNCTION; DISEASE SEVERITY; ENDOTHELIUM; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HEART DEATH; HEMOSTASIS; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INCIDENCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; METABOLIC RATE; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; ENERGY METABOLISM; FEMALE; HEMOSTASIS; HORMONES; HUMANS; POLYCYSTIC OVARY SYNDROME; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84859486231     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2012.01.001     Document Type: Review

References (64)

1. Alexander C.J., Tangchitnob E.P., Lepor N.E. Polycystic ovary syndrome: A major unrecognized cardiovascular risk factor in women. Rev Cardiovasc Med 2009, 10:83-90.
2. Andiran N., Yordam N., Kirazli S. Global fibrinolytic capacity is decreased in girls with premature adrenarche: A new pathological finding?. J Pediatr Endocrinol Metab 2005, 18:1373-1381.
3. Atiomo W.U., Bates S.A., Condon J.E., et al. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998, 69:236-241.
4. Atiomo W.U., Fox R., Condon J.E., et al. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxford) 2000, 52:487-492.
5. Atiomo W.U., Hilton D., Fox R., et al. Immunohistochemical detection of plasminogen activator inhibitor-1 in polycystic ovaries. Gynecol Endocrinol 2000, 14:162-168.
6. Azziz R. Epidemiology and pathogenesis of the polycystic ovarian syndrome in adults [Online] Accessed May 1, 2010. http://www.uptodateonline.com/patients/content/topic.do?topicKey=~NAVVNsjaPQ1Rair.
7. Azziz R., Marin C., Hoq L., et al. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 2005, 90:4650-4658.
8. Berneis K., Rizzo M., Lazzarini V., et al. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007, 92:186-189.
9. Boulman N., Levy Y., Leiba R., et al. Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease. J Clin Endocrinol Metab 2004, 89:2160-2165.
10. Carmassi F., De Negri F., Fioriti R., et al. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. Thromb Res 2005, 116:207-214.
11. Cascella T., Palomba S., De Sio I., et al. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod 2008, 23:153-159.
12. Charitidou C., Farmakiotis D., Zournatzi V., et al. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels in women with the polycystic ovary syndrome. Atherosclerosis 2008, 196:958-965.
13. Chen C.C., Lee K.D., Gau J.P., et al. Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation. Ann Hematol 2005, 84:675-680.
14. Dahlgren E., Janson P.O., Johansson S., et al. Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril 1994, 61:455-460.
15. De Pergola G., De Mitrio V., Giorgino F., et al. Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: Relationship with body fat distribution. Int J Obes Relat Metab Disord 1997, 21:527-535.
16. Demirel F., Bideci A., Cinaz P., et al. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. Clin Endocrinol (Oxford) 2007, 67:129-134.
17. Dereli D., Ozgen G., Buyukkececi F., et al. Platelet dysfunction in lean women with polycystic ovary syndrome and association with insulin sensitivity. J Clin Endocrinol Metab 2003, 88:2263-2268.
18. Diamanti-Kandarakis E., Palioniko G., Alexandraki K., et al. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol 2004, 150:793-798.
19. Erdogan M., Karadeniz M., Alper G.E., et al. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2008, 116:143-147.
20. Glueck C.J., Morrison J.A., Wang P. Insulin resistance, obesity, hypofibrinolysis, hyperandrogenism, and coronary heart disease risk factors in 25 pre-perimenarchal girls age < or =14 years, 13 with precocious puberty, 23 with a first-degree relative with polycystic ovary syndrome. J Pediatr Endocrinol Metab 2008, 21:973-984.
21. Glueck C.J., Wang P., Goldenberg N., Sieve L. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin Appl Thromb Hemost 2004, 10:323-334.
22. Gursoy A., Ertugrul D.T., Pamuk B., et al. Mean platelet volume in patients with polycystic ovary disease. Platelets 2006, 17:505-506.
23. Heinrich J., Dirkeskersting A., Schulte H., Assmann G. Effects of age, menopause and human growth-hormone on variables of fibrinolysis. Fibrinolysis 1992, 6:33-35.
24. Heutling D., Schulz H., Nickel I., et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 2008, 93:82-90.
25. Ibanez L., Aulesa C., Potau N., et al. Plasminogen activator inhibitor-1 in girls with precocious pubarche: A premenarcheal marker for polycystic ovary syndrome?. Pediatr Res 2002, 51:244-248.
26. Karakurt F., Gumus I.i., Bavbek N., et al. Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome. Gynecol Endocrinol 2008, 24:491-497.
27. Kebapcilar L., Bilgir O., Taner C.E., et al. Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients. Arch Gynecol Obstet 2010, 281:539-543.
28. Kebapcilar L., Taner C.E., Kebapcilar A.G., Sari I. High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet 2009, 280:187-193.
29. Kelly C.J., Lyall H., Petrie J.R., et al. A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2002, 87:3287-3290.
30. Kielstein J.T., Donnerstag F., Gasper S., et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006, 37:2024-2029.
31. Kuscu N.K., Var A. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2009, 88:612-617.
32. Lin S., Yongmei G. Plasminogen activator and plasma activator inhibitor-1 in young women with polycystic ovary syndrome. Int J Gynaecol Obstet 2008, 100:285-286.
33. Luque-Ramirez M., Mendieta-Azcona C., Del Rey Sanchez J.M., et al. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: Influence of obesity and smoking. Eur J Endocrinol 2009, 160:469-480.
34. Macut D., Micic D., Cvijovic G., et al. Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome (PCOS). J Pediatr Endocrinol Metab 2001, 14(Suppl 5):1353-1359. 1365.
35. March W.A., Moore V.M., Willson K.J., et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010, 25:544-551.
36. Meinitzer A., Puchinger M., Winklhofer-Roob B.M., et al. Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method. Clin Chim Acta 2007, 384:141-148.
37. Meyer C., McGrath B.P., Teede H.J. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007, 30:471-478.
38. Moran L.J., Brinkworth G., Noakes M., Norman R.J. Effects of lifestyle modification in polycystic ovarian syndrome. Reprod Biomed Online 2006, 12:569-578.
39. Moran L.J., Hutchison S.K., Meyer C., et al. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome. Clin Sci (London) 2009, 116:761-770.
40. Nasiek M., Kos-Kudla B., Ostrowska Z., et al. Acute phase proteins: C-reactive protein and fibrinogen in young women with polycystic ovary syndrome. Pathophysiology 2007, 14:23-28.
41. Oktem M., Ozcimen E.E., Uckuyu A., et al. Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease. Fertil Steril 2009, 91:2545-2550.
42. Oral B., Mermi B., Dilek M., et al. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome. Gynecol Endocrinol 2009, 25:110-116.
43. Orio F., Palomba S., Cascella T., et al. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?. Reprod Biomed Online 2004, 9:505-510.
44. Ota S., Wada H., Abe Y., et al. Elevated levels of prothrombin fragment 1 + 2 indicate high risk of thrombosis. Clin Appl Thromb Hemost 2008, 14:279-285.
45. Ozgurtas T., Oktenli C., Dede M., et al. Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis 2008, 200:336-344.
46. Pamuk B.O., Torun A.N., Kulaksizoglu M., et al. Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters. Fertil Steril 2010, 93:1227-1233.
47. Rajendran S., Willoughby S.R., Chan W.P., et al. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis 2009, 204:509-514.
48. Sampson M., Kong C., Patel A., et al. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxford) 1996, 45:623-629.
49. Schadinger S.L., Boffa M.B. Active platelet-derived TAFI attenuates platelet-rich thrombus lysis in vitro. J Thromb Haemost 2009, 7(Suppl 2):313-314.
50. Shaw L.J., Bairey Merz C.N., Azziz R., et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: Results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008, 93:1276-1284.
51. Sills E.S., Drews C.D., Perloe M., et al. Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system. Gynecol Endocrinol 2003, 17:231-237.
52. Slopien R., Lewandowski K., Kolacz E., et al. Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity. Gynecol Endocrinol 2006, 22:651-654.
53. Teede H., Deeks A., Moran L. Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010, 8:41.
54. Teede H.J., Misso M.L., Deeks A.A., et al. Assessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline. Med J Aust 2011, 195:s65-s112.
55. Tsanadis G., Vartholomatos G., Korkontzelos I., et al. Polycystic ovarian syndrome and thrombophilia. Hum Reprod 2002, 17:314-319.
56. Urbanek M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2007, 3:103-111.
57. Vague P., Juhan-Vague I., Aillaud M.F., et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986, 35:250-253.
58. Van Tilburg N.H., Rosendaal F.R., Bertina R.M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000, 95:2855-2859.
59. Wannamethee S.G., Lowe G.D., Shaper A.G., et al. The metabolic syndrome and insulin resistance: Relationship to haemostatic and inflammatory markers in older non-diabetic men. Atherosclerosis 2005, 181:101-108.
60. Wild R.A., Carmina E., Diamanti-Kandarakis E., et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010, 95:2038-2049.
61. Worboys S., Kotsopoulos D., Teede H., et al. Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab 2001, 86:158-161.
62. Yarali H., Yildirir A., Aybar F., et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001, 76:511-516.
63. Yildiz B.O., Haznedaroglu I.C., Kirazli S., Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab 2002, 87:3871-3875.
64. Zwirska-Korczala K., Sodowski K., Konturek S.J., et al. Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome. J Physiol Pharmacol 2008, 59(Suppl 2):161-178.